<DOC>
	<DOCNO>NCT00435669</DOCNO>
	<brief_summary>The purpose trial determine mass balance , pharmacokinetics , metabolism , rout extent elimination BMS-582664</brief_summary>
	<brief_title>A Phase I Study Determine Absorption , Distribution , Metabolism , Elimination Single Radiolabeled Dose Brivanib ( BMS-582664 )</brief_title>
	<detailed_description />
	<criteria>Histologic/cytologic diagnosis advance metastatic solid tumor ECOG 02 4/6 week since prior therapy Brain metastasis Secondary primary malignancy Thromboembolic disease require full anticoagulation within 6 month Inability swallow absorb oral therapy Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Advanced metastatic solid tumor</keyword>
</DOC>